First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

Bookmark and Share
Published: 16 Apr 2021
Views: 628
Dr Martina Lorenzi - University of Padua, Padua, Italy

Dr Martina Lorenzi speaks to ecancer about the efficacy of the first-line osimertinib in EGFR mutant aNSCLC patients. The study evaluates the progression pattern and safety of this drug in the real world. Initially, she explains the background of the study.

Dr Lorenzi then discusses the methodology and the results of her research.

This study confirmed osimertinib efficacy and safety in the real world.

In this research thromboembolic events were observed more frequently than previously reported. In the end, she says that the study is still ongoing to recruit a larger patient population.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.